Question

Hearts ‘R Us ("Hearts" or "the Company") is an early-stage research and development medical device company. Hearts has no current products in the marketplace but is in the final stages of going to market with the Heart Valve System. All preliminary trials have been approved by the FDA, and the Company is in the final trial; once the final trial is complete, the Company will present the product to the FDA for final approval. If approved by the FDA, the Heart Valve System will revolutionize the way medical professionals repair heart valve defects.

Answer 1

Full question attached

Answer and Explanation:

1. Hearts R Us should account for the preferred shares series A financing as equity at issuance since it is not mandatory to redeem at issuance according to ASC 480-10-15-3

2. Here Hearts R Us may have to reclassify the preferred shares series A financing from Bionic considering no FDA approval yet and the failure of the heart valve product. Bionic has the option/right to redeem at par value in the fifth year if there is no FDA approval and so Hearts R Us would have to buy back the security from Bionic at par value(amount sold to Bionic) and classify as common stock.